<DOC>
	<DOC>NCT02402699</DOC>
	<brief_summary>This protocol is being conducted to comply with the direct request from the Taiwan Food and Drug Administration (TFDA) for a 60-month intensive pharmacovigilance protocol of patients with known hepatitis B (HBV) or hepatitis C (HCV) infection, regardless of control on antiviral therapy in Taiwan and who are treated with ipilimumab for advanced (unresectable, recurrent or metastatic) Melanoma.</brief_summary>
	<brief_title>Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Age of 18 years or older on date of first dose of Ipilimumab Patients who received at least 1 dose of Ipilimumab for the treatment of unresectable, recurrent or Metastatic Melanoma in Taiwan Patients with advanced Melanoma and HBV or HCV who are initiating Ipilimumab under the discretion of their physician Patients who received Ipilimumab as part of a clinical trial Patients who are receiving Ipilimumab for any indication other than local approval (ie, unresectable or Metastatic Melanoma) Patients who are not infected with HBV or HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HBV</keyword>
	<keyword>HBC</keyword>
</DOC>